Press releases
Browse LEO Pharma’s global press releases intended for media.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis
Timber Pharmaceuticals, Inc., a LEO Pharma Company, provides an update on the development program for TMB-001 in congenital ichthyosis MADISON, NEW JERSEY, August 21, 2024 – Timber Pharmaceuticals Inc.,…
-
Change in the Board of Directors of LEO Pharma
Change in the Board of Directors of LEO Pharma Ballerup, Denmark, July 31, 2024 – Today, LEO Pharma A/S announced that non-executive director Jan van de Winkel has decided…
-
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales
LEO Pharma continues to deliver double-digit revenue growth backed by strong dermatology sales Ballerup, Denmark, 31 October, 2024 – In the first nine months of 2024, LEO Pharma delivered…
-
LEO Pharma announces changes to its Global Leadership Team
LEO Pharma announces changes to its Global Leadership Team LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to…
-
Recognized professor joins LEO Pharma to accelerate external innovation
Recognized professor joins LEO Pharma to accelerate external innovation LEO Pharma has appointed Dr. Lars Erik Vølund Kristensen as Vice President, Head of External Innovation, effective June 1,…
-
Solid start to the year: 13% revenue growth driven by strong performance in dermatology
Solid start to the year: 13% revenue growth driven by strong performance in dermatology Ballerup, May 3, 2024. – In Q1 2024, LEO Pharma delivered a revenue growth…
-
LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals.
LEO Pharma finalizes acquisition of key assets from Timber Pharmaceuticals. Strategic acquisition to expand pipeline, accelerate growth, and meet unmet needs in medical dermatology. Ballerup January 23, 2024 –…
-
Globally known professor and dermatologist joins LEO Pharma
Globally known professor and dermatologist joins LEO Pharma Ahead of EADV, LEO Pharma announces that Professor Alexander Egeberg, a board-certified dermatologist, and top key opinion leader, will join…
-
LEO Pharma delivers solid first half-year results and strengthens its capital structure
LEO Pharma delivers solid first half-year results and strengthens its capital structure Ballerup, September 12, 2023 – Today, LEO Pharma announced results for first half 2023 and an…
-
LEO Pharma announces changes to its Global Leadership Team
LEO Pharma announces changes to its Global Leadership Team Ballerup, August 28, 2023 – Today, LEO Pharma announced the appointment of Nathalie Daste as new Executive Vice President,…
Media Inquiries
Head of Media
+4530502014
JEILK@leo-pharma.com
SVP, Head of Corporate Communications
+4529407016
ANMRN@leo-pharma.com
Media Manager
+4553748849
CHBUN@leo-pharma.com
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request. For updated information about clinical trials, please visit https://clinicaltrials.gov/.